CD52 is a protein present on a cell surface of the vast majority of all lymphoid cells and many other hematopoietic cells but not on stem cells. This antigenis a target for monoclonal antibody therapy (Campath). This antigen is currently not detectable in formalin-fixed, paraffin-embedded mate...
One trial involving SSEA-1 in therapy used an antibody called FC-2.15, which was later determined to recognize the LeXepitope[259]. Mordoh et al. generated this IgM monoclonal antibody by immunizing Balb/c mice with tumor cells from an undifferentiated human primarybreast carcinoma[260]. FC-...
group may benefit from analysis of the tumor-associated macrophage marker CD68, which can be used to predict adverse outcomes of cHL [4], the prediction is controversial [5]. The antibody conjugate drug brentuximab vedotin targets CD30. In clinical trials, brentuximab vedotin therapy improved ...
Background KIR3 DL2, an inhibitory receptor expressed by natural killer cells and a subset of normal CD8+ T cells, is aberrantly expressed in neoplastic cells in transformed mycosis fungoides and S茅zary syndrome. Anti- KIR3 DL2 targeted antibody therapy has shown potent activity in ...
In this scenario, anti-TNF plus anti-TL1A combi- nation therapy may be beneficial, especially in those patients with high TNFa and TL1A levels. In addition, those CD patients who have become refractory to anti-TNFa therapies may use the TL1A pathway to bypass the need for TNFa to drive ...
提要:目的观察芳维A酸乙酯(arotinoidethylester,AE)在HL260细胞分化成熟过程中对其CD11b、CD15表达的影响,初步探讨AE治疗脓疱型银屑病的可能机制。方法HL260细胞以二甲基亚砜(dimethylsulfoxide,DMSO)、全反式维A酸(all2trans2retinoicacid,ATRA)、AE诱导培养,5d后用流式细胞仪检测HL260细胞表面CD11b和CD15的表达。
“Many of us have seen first-hand the devastation of Alzheimer’s. More than anything we wanted to succeed in finding a meaningful therapy... [Pfizer scientists’] efforts have vastly contributed to the broad scientific understanding of Alzheime...
To test the preclinical potential of bispecific antibody therapy against an endogenously arising solid brain tumor, we have utilized a novel variation of conventional bispecific antibodies, referred to as bispecific ligand-antibody conjugates, to target choroid plexus tumors. The bispecific ligand-antibody...
We acknowledge Dr Al-Shamkhani for the mouse anti-TL1A antibody. We thank MD Biosciences for running the TNBS model and subsequent analysis. We thank Gang Chen for project support. Finally, we thank Alain Tissot for project insight and support and Chris Kitson, Franck Barrat, and Thomas Tan ...
“Many of us have seen first-hand the devastation of Alzheimer’s. More than anything we wanted to succeed in finding a meaningful therapy... [Pfizer scientists’] efforts have vastly contributed to the broad scientific understanding of Alzhe...